Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The Japanese automakers had announced a plan to combine in December. The tech giant's fast-growing cloud-computing business decelerated last quarter. Shares were off more than 7% after hours.

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.